Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bit Digital Inc (BTBT) vs Pfizer Inc (PFE) Price & Performance

Bit Digital IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Bit Digital Inc vs Pfizer Inc — how do they compare? Bit Digital Inc trades at $1.35 (market cap $453.60M), while Pfizer Inc trades at $26.55 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 339.9× Bit Digital Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Bit Digital Inc pays none. Which is the better fit depends on your goals.

BTBTPFE
Market Cap
$453.60M$154.18B
Sector
TechnologyHealth
52-Week High
$4.22$28.56
52-Week Low
$1.23$23.60
Enterprise Value
$742.91M$205.67B
Volume
29,869,932
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bit Digital Inc

BTBT trades at $1.38 with a 1.1% daily gain, showing modest momentum despite a bearish technical signal from moving averages. The company reported revenue of $113.56M in 2025 but posted a significant net loss of $80.32M, with profitability metrics like ROE at -38.98% indicating financial strain. Analyst coverage remains limited but unanimously positive, with 2 buy ratings and no hold or sell recommendations. Recent news highlights upcoming Q2 2026 earnings and mixed price target discussions.

The outlook for BTBT is clouded by persistent losses and negative cash flow from operations, though financing activities provide liquidity. Investment opportunities hinge on a potential earnings turnaround, while risks include sustained unprofitability, competitive pressures, and reliance on external funding. The stock's low valuation multiples may attract value seekers, but caution is warranted given the fundamental challenges.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bit Digital Inc

Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.

Read more on BTBT

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE